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Abstract
Background: Mitochondria provide most of the energy for brain cells by the process of oxidative phosphorylation.
Mitochondrial abnormalities and deficiencies in oxidative phosphorylation have been reported in individuals with
schizophrenia (SZ), bipolar disorder (BD), and major depressive disorder (MDD) in transcriptomic, proteomic, and
metabolomic studies. Several mutations in mitochondrial DNA (mtDNA) sequence have been reported in SZ and BD
patients.
Methodology/Principal Findings: Dorsolateral prefrontal cortex (DLPFC) from a cohort of 77 SZ, BD, and MDD subjects and
age-matched controls (C) was studied for mtDNA sequence variations and heteroplasmy levels using Affymetrix mtDNA
resequencing arrays. Heteroplasmy levels by microarray were compared to levels obtained with SNaPshot and allele specific
real-time PCR. This study examined the association between brain pH and mtDNA alleles. The microarray resequencing of
mtDNA was 100% concordant with conventional sequencing results for 103 mtDNA variants. The rate of synonymous base
pair substitutions in the coding regions of the mtDNA genome was 22% higher (p=0.0017) in DLPFC of individuals with SZ
compared to controls. The association of brain pH and super haplogroup (U, K, UK) was significant (p=0.004) and
independent of postmortem interval time.
Conclusions: Focusing on haplogroup and individual susceptibility factors in psychiatric disorders by considering mtDNA
variants may lead to innovative treatments to improve mitochondrial health and brain function.
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Introduction
Mitochondrial DNA (mtDNA) mutations can alter functions
involving apoptosis, calcium buffering and signaling, and the
brain’s capacity to meet critical energy oxidative phosphorylation
(OXPHOS) demands. The inheritance of mtDNA is normally
matrilineal [1]. High rates of maternal offspring of SZ [2,3,4,5]
and BD [6] compared to paternal rates have been primarily found
in family studies [7,8] but not in the general population [9,10,11].
This supports the hypothesis that increased risk for these disorders
might be related to mitochondrial dysfunction. Failure to find a
pattern of maternal inheritance as well as evidence of paternal
inheritance have also been reported in SZ and BD [12,13].
Tissues with high energy requirements seem to accumulate
mtDNA mutations more readily; thus, in general, the accumula-
tion of mtDNA mutations is proportional to their metabolic rate
[14]. Multiple mechanisms across the life span exist for
transmission of mtDNA mutations [15,16]. A cell may become
heteroplasmic (increase of intra individual sequence variability in
mtDNA) through a germ line or an acquired somatic mutation;
thus, heteroplasmy may be inherited or acquired [17,18]. MtDNA
has been suggested as a potential ‘‘weak point’’ of the genome [19]
due to susceptibility to somatic deletions as mtDNA is not
protected by histones and lacks the repair machinery associated
with nuclear DNA [20] which is one reason there is a higher rate
of mutation or base pair substitutions in mtDNA compared to
nuclear DNA. Heteroplasmic events in brain appear to be
common in several studies [21,22,23,24,25]. Small changes in
the level of heteroplasmy may be clinically relevant, and can
appear in vulnerable cells and tissues in neurodegenerative
disorders such as Parkinson’s, Huntington’s, and Alzheimer’s
Disease [16,26,27], suggesting a critical threshold of heteroplasmic
PLoS ONE | www.plosone.org 1 March 2009 | Volume 4 | Issue 3 | e4913mutation above which functional deficits and neuropathological
damage occurs.
Evidence for dysfunction of mitochondria in psychiatric
disorders
Psychiatric symptoms have been documented in subjects with
mitochondrial disease [28,29,30]. Conversely, increased psychiat-
ric symptoms have been associated with declines in mitochondrial
functional activity [31,32,33,34]. The neuroimaging literature
suggests that energy metabolism abnormalities are widespread in
the brains of subjects with SZ [35,36,37,38], BD [39,40,41,42],
and MDD [43].
Common, novel, and ethnic specific defining haplogroup
mitochondrial SNPs are associated with psychiatric
disorders
Sequence variations in the mitochondrial genome are implicat-
ed in the pathogenesis of SZ and BD [44,45,46,47,48,
49,50,51,52,53,54,55,56,57,58]. ND1, ND3, ND4, and ND5
SNPs have been associated with SZ or BD [51,52,59,60]. An
interesting SNP, the ND3 A10398G polymorphism, may be
related to lithium response in BD [61] as well as increased pH in
cybrid cells [62].
Ethnic specific defining haplogroup SNPs are also reported to
be associated with psychiatric disorders. The sub-haplogroup F1ba
of the haplogroup N, may harbor a haplotype risk factor for
atypical psychosis [63] and in an Israeli sample of SZ there was an
over-representation of the HV mtDNA haplogroup [64]. Several
attempts have been made to assess association of certain mtDNA
genetic variants with BD [44] in haplogroup T. A recent report
indicated that the number of synonymous substitutions was
increased in mtDNA obtained from blood samples in SZ [58],
independent of haplogroup.
Based upon the studies implicating mitochondrial dysfunction in
psychiatric disorders, the present study measured mtDNA variants
in brain tissue, including substitutions, synonymous and non-
synonymous, and rare variants, which could predispose to BD,
MDD, and SZ. Secondly, we compared heteroplasmy detection by
microarray using a published method [65] to conventional
methods. Thirdly, this study examined the association between
brain pH and mtDNA alleles. The hypothesis that mtDNA
variants might influence brain pH is supported by the haplogroup
defining ND3 A10398G polymorphism associated with an
increased pH in cybrid cells [62]. Further, microarray studies
have demonstrated differential nuclear-encoded mitochondrial
gene expression [45,66,67] as well as mitochondrial gene
expression [67] related to mean group pH differences.
31P
magnetic resonance spectroscopy findings have also indicated a
decrease in intracellular pH in BD [68] increasing the potential
relevance of such an effect on psychiatric disorders.
Results
Microarray resequencing arrays and capillary
electrophoresis sequencing of mtDNA
The Affymetrix Genetic Sequence Analysis Software (GSEQ)
assigned high quality base pair sequencing calls (T,C,G,A) to
98.2% of the mtDNA genome on all 77 chips analyzed. There was
a 100% concordance between microarrays resequencing the same
individual repeated de novo. The call rate did not depend on the
source of starting genomic DNA, as call rates from 8 freshly
prepared lymphocyte samples were also 98.2% on average in the
investigator’s laboratory. Three individual mtDNA genomes were
previously sequenced on an ABI 3130 capillary electrophoresis
(CE) sequencer. All 103 calls that were different from the rCRS
were 100% concordant between microarray and CE sequencing in
these three individuals. The present mitochondrial microarray
resequencing results are consistent with additional experimental
verification from other investigators showing at least 99.99%
microarray accuracy compared to sequencing [65,69,70,71,
72,73,74,75]. In addition, the microarray procedure detected the
known heteroplasmic mutation A5793G with 45% heteroplasmy
[65]. The same subject was found to be 30% heteroplasmic by
PCR-RFLP analysis. Taken together, these initial results con-
firmed the mitochondria resequencing array is a useful tool for
resequencing.
Haplogroup differences in psychiatric disorders
Upon completion of the resequencing arrays, the 77 mtDNA
sequences from DLPFC were aligned with the rCRS. A
phylogenetic tree (Fig. 1) was reconstructed with the MRBAYES
program, which is a variant of the Markov chain Monte Carlo
method [76,77].
The rCRS clustered far from the ancestral L haplogroup, and
was correctly placed within the H haplogroup with an H2 subject
as the nearest neighbor (Fig. 1). Individuals within each
haplogroup are joined neighbors except for the node labeled M,
N1B1, pre HV, which placed these three haplogroups as closest
neighbors. One reason these haplogroups did not cluster
separately as expected was that each of these samples also carried
a high rate of synonymous substitutions (shown in the next
section). The majority of 17 individuals (88%–100%) in this cluster
carried mtSNPs different from rCRS at the following positions:
9540, 10652, 12705, 14783, 15043, 16311, 16325. The underlined
mtSNPs were found in the M, N, or D haplogroups (/http://www.
mitomap.org/mitomap-phylogeny.pdf). The 10652 mtSNP was
found in one L2b individual (Mitokor 568 sequence [78]); 16325
and 16311 were not found in a specific haplogroup.
Previous haplogroup findings that were reported for BD [44]
indicated a slight over-representation in the T haplogroup, thus
the T haplogroup was explored further in the current dataset. The
opposite finding emerged, controls were significantly over-
represented in haplogroup T compared to BP+SZ (p=0.04
permuted p-value). There was complete concordance of findings
for all nine SNPs defining this haplogroup (709, 1888, 4917, 8697,
10463, 13368, 14905, 15607, 15928). This concordance illustrates
confidence for haplogroup assignment using microarray resequen-
cing.
Another exploratory difference in the distribution of psychiatric
groups by haplogroup (Table 1) was seen in analysis of the
combined BD+SZ distribution of subjects found more frequently
in the pre HV group (Table 2) compared to all haplogroups (Chi
square=13.7, df (6), p=0.032). To further test for association of
mtDNA SNPs we analyzed the SZ, BD, MDD mtDNA SNPs
dataset (484 polymorphisms) using PLINK [79].
Case-control differences in polymorphisms
An allelic association analysis was conducted across polymor-
phic sites in mtDNA sequence from the 77 subjects. Permutation
analysis (n=50,000) for each polymorphism was run using PLINK
[79] to establish an empirical p-value for SZ v C, MDD v C, and
BD v C comparisons. There were 484 nominal polymorphic sites,
and in this first pass analysis, all SNPs were calculated for
association, without regard to haplogroup specificity or minor
allele frequency. Only empirical p-values,0.05 are reported for
case-control comparisons (Table 3). There were two 12S rRNA
rare polymorphisms found in SZ and not in C. The 12S mtDNA
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SZ, respectively. Both substitutions have been reported in 2,704
mtDNA sequences at a rate of 0.008 for G750A and 0.032 for
G1438A [80]. The empirical p-values for association with G750A
and G1438A were 0.037 and 0.012, respectively. The ND2 gene
G4769A synonymous substitution showed a significant allelic
association with SZ (empirical p value 0.037).
For BD, there were three allelic associations significant in the D-
loop control region: T114C (p=0.032), C195T (p=0.008), and
G16300A (p=0.012). The T114C and G16300A minor alleles are
rare at 0.004 and 0.003 in a database of 2,704 mtDNA genomes
[80]. Three associations for MDD are shown in Table 3.
Microarray Heteroplasmy
The present microarray data shows the ND4L T10652C variant
appears within the N (N1B1, pre HV) and M (D1) haplogroups.
There were 17 subjects within these haplogroups that had a
heteroplasmy level greater than 50% by microarray calculation as
previously described [65]. This ND4L T10652C transition is rare
and was not present in a human mtDNA database of 2,704
sequences distributed among major haplogroups [80]. In addition
it was not observed in 12 mtDNA samples from control blood
measured by microarray resequencing, reducing the likelihood of a
microarray artifact. There was a common haplotype for the
putative T10652C individuals at four mtSNPs – T10652C,
Figure 1. Phylogenetic tree of human mtDNA coding sequence variants demonstrating regional association of haplogroups using
mtDNA sequence from DLPFC. Haplogroups, groups of related haplotypes, are derived from a founding haplotype, harboring characteristic
mtDNA sequence polymorphisms. Each haplogroup is designated by a letter in this tree, the RCRS is the reference sequence; the ticks around the
perimeter of the circle represent the individual mtDNA sequences from DLPFC. The faint numbers represent the probability of support for the
branches which was 0.9–1.The mtDNA haplogroups have proven to be highly geographically associated [109]. The haplogroup assignments were
calculated at MITOMASTER (http://mammag.web.uci.edu/twiki/bin/view/Mitomaster/WebHome) using all mtDNA sequence base pairs.
doi:10.1371/journal.pone.0004913.g001
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three mtSNPs appear early in the phylogenetic mtDNA
evolutionary tree at L2b, and the roots of M, and N. A post hoc
analysis of each SNP was run separately and pooled for the three
psychiatric groups (SZ, BD and MDD) and compared to controls.
A trend for an association for each SNP was found (T14783C
p=0.06, G15043A p=0.07, T9540C p=0.16). These observa-
tions prompted further investigation of the variant by sequencing,
SNaPshot, and allele specific PCR. The ND4L T10652C variant
was confirmed by direct sequencing of mtDNA for the highest
heteroplasmic individual (81% C heteroplasmy by microarray
calculation) within the D1 haplogroup who was an MDD subject
and had the C allele (Fig. 2). The other 16 individuals within the N
(N1B1, pre HV) and M (D1) haplogroups showed the T allele with
direct sequencing. The heteroplasmy detection limit of conven-
tional direct CE sequencing is 20%–30% [81,82], indicating that
the microarray results were inflated for these subjects. All subjects
were resequenced 100 bp on either side of the ND4L T10652C
for insertions or deletions. There were no insertions or deletions
found suggesting that the microarray results were not due to probe
mismatches. Primers used for sequencing and allelic specific PCR
did not amplify genomic DNA extracted from ru cells depleted of
mtDNA [83].
SNaPshot multiplex was tried for validation of the microarray
calls at T10652C. Twenty four subjects with varying heteroplasmy
levels by microarray were run and all individuals showed the T
allele indicating their heteroplasmy levels, if present, were below
the detection limit of this method. Although we ran a standard
curve consisting of dilutions from 100% down to 0.1% for the C
allele, we were only reliably able to detect 5% or greater
heteroplasmy using SNaPshot.
A more sensitive method for validation of the calculated
heteroplasmy from the microarray resequencing data was
performed with an allelic specific real-time detection and
quantification experiment for the T10652C variant (Fig. 3). The
subject with the highest heteroplasmy in the initial microarray
experiment (81%) showed similar levels in the confirmation
experiment (88%). Because the allelic specific experiment can
detect low levels of heteroplasmy (0.25%), we were able to detect
several other subjects with heteroplasmy .0.25%. Two SZ
subjects (from haplogroups pre HV and M) with 69% and 58%
heteroplasmy in the microarray experiment had 0.47% hetero-
plasmy in the real-time allelic specific qPCR experiment. Despite
the failed confirmation of some of the microarray results with 50%
and higher heteroplasmy, the three subjects with somewhat higher
levels of heteroplasmy were all psychiatric subjects.
Substitution bias in subjects with psychiatric disorders
and controls
One measure of neutrality for mtDNA variants was calculated
by comparing the number of non synonymous substitutions (dN) to
the number of synonymous substitutions (dS) in each group.
Although it is generally accepted that S changes are greater than N
changes in mtDNA, we tested for differences between groups in
this rate using pair wise comparisons. Values of p,0.05 were
considered significant and tabulated (Table 4, column [A] shows
the number of significant pair wise comparisons). Table 4 shows
the number of times the null hypothesis of strict-neutrality
(dN=dS) was accepted in [B] or rejected in favor of the
alternative hypothesis (dN,dS, column [A]) using pair wise
comparisons for all possible subject combinations of BD-C, SZ-C,
MDD-C, and C-C. Occurrences that were significant are counted
in column [A]. The higher rate of synonymous substitutions in
Table 1. The haplogroup determination of mtDNA derived
from DLPFC showed 31 diverse haplogroups that could be
reconstructed.
Haplogroup BD Control MDD SZ
B2 1 0 0 0
B4a 0 1 0 0
B4b 0 1 0 0
C2 0 1 0 0
D1 0 0 1 0
H1 1 5 0 1
H2 0 0 0 3
H3 0 3 2 1
HV 0 2 0 0
I1 0 1 0 0
J1c 1 2 0 1
J2 1 0 0 0
J3 0 1 0 0
K1 2 2 1 2
K2 0 1 0 0
L1b 0 0 0 1
L1c 0 1 0 0
L2a 0 2 0 0
M0 2 1 2
N1B1 1 1 3 1
Pre HV 3 1 0 1
R1 0 1 0 0
T1 0 1 0 0
T2 0 3 2 0
T2a 0 1 0 0
U2 0 0 1 0
U5a 1 2 2 0
U6 0 0 1 0
V2 0 0 0 1
V3 0 1 0 0
X2 1 0 1 0
Total 12 36 15 14
doi:10.1371/journal.pone.0004913.t001
Table 2. The haplogroup determination of mtDNA derived
from DLPFC was condensed from Table 1 and showed that BD
and SZ were over-represented in Pre HV haplogroup and
MDD was over-represented in the ‘‘other’’ haplogroups.
Haplogroup6Psychiatric Diagnosis
Diagnosis H,HV, V Pre HV Others
Bipolar Disorder 13 8
Control 11 1 24
Major Depressive Disorder 20 1 3
Schizophrenia 61 7
The chi-square for this table is (chi-square=13.7 (6), p=0.032).
doi:10.1371/journal.pone.0004913.t002
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(p=0.0017).
A second analysis of the overall transition/transversion bias (R)
for all DLPFC mtDNA sequences was conducted using the
Maximum Composite Likelihood method in MEGA4 [84,85] for
each of the four groups separately. Codon positions included were
1st, 2nd, 3rd. The observed transition/transversion ratios were
2.25 fold higher in SZ compared to C (Table 5). This suggests a
higher number of substitutions in DLPFC in SZ compared to
controls in the 13 mtDNA transcripts. Two caveats apply to this
difference in bias: the overall sample size is small (n=77) and the
total number of transversions in the entire sample was modest
(n=22) which can inflate R. Further, we used a homogeneous
model to assume that all sites are variable, and may over estimate
the number of substitutions based upon pairs of sequences. With
these caveats, Tables 4 and 5 consistently showed the number of
substitutions in SZ pair wise comparisons exceeded the rate in
control comparisons and the overall R rate is higher in SZ than in
C. The present R ratio (transition/transversion) data was
examined in the coding region functional grouping level by
complex, the rate for R in mitochondrial complex I was 10 fold
higher in SZ compared to controls.
Association with postmortem pH
Postmortem pH was next analyzed for association with mtDNA
SNPs. Association and permutation analysis were conducted in
PLINK and the permuted p-values that were most significant for
the association of pH were three mtDNA SNPs in tRNA Leu,
ND4, and ND5 (association p-values 0.002–0.0004, Table 6).
These same three mtDNA SNPs are ethnic-specific haplotype-
defining polymorphisms for the super haplogroup cluster (U, K,
UK) and all subjects with these three mtDNA SNPs were assigned
Table 3. Mitochondrial polymorphisms were analyzed in PLINK for allelic association with 50,000 case-control permutations to
obtain empirical p-values.
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BD 114 D-loop T 0.250 0.030 C 0.032 0.0048 51.56 C 1856 9
BD 195 D-loop C 0.571 0.125 T 0.007 0.1779 3.21 T 11 280 1574
BD 10652 ND4L C 0.333 0.086 T 0.037 0.0000 T 2704
BD 16300 D-loop G 0.167 0.000 A 0.014 0.0032 51.70 A 1861 6
SZ 750 12S rRNA A 0.143 0.000 G 0.037 0.0082 17.42 G 22 2682
SZ 1438 12S rRNA A 0.214 0.000 G 0.012 0.0321 6.68 A 84 2620
SZ 4769 ND2 A 0.143 0.000 G 0.037 0.0112 12.74 A 30 2674
MDD 10652 ND4L C 0.333 0.086 T 0.026 0.0000 T 2704
MDD 14668 ND6 T 0.133 0.000 C 0.042 0.1118 1.19 C 2432 272
MDD 15043 Cytb A 0.400 0.143 G 0.042 0.4032 0.99 G 777 1927
The number of individuals with mtDNA alleles shown in the far right columns is from the Ingman mt database (URL http://www.genpat.uu.se/mtDB/). A preliminary
odds-ratio was calculated by comparing the affected allele frequency to the Ingman database [80]. All case-control differences were either in the control region, or a
synonymous substitution in the third position in coding regions.
doi:10.1371/journal.pone.0004913.t003
Figure 2. Electropherogram results for direct sequencing of the ND4L T10652C variant. (A) is the ‘T’ allele sequencing result from the
lowest heteroplasmic individual used to make the ‘T’ allele clone standard for SNaPshot and allele specific PCR. (B) is the ‘C’ allele sequencing result
from the highest heteroplasmic individual detected with microarray (MDD subject from haplogroup D1) used to make the ‘C’ allele clone standard.
doi:10.1371/journal.pone.0004913.g002
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mitomaster.org). This super haplogroup (U, K, UK) had a
significantly higher postmortem pH (7.0060.18 SD) compared
to the remaining subjects pH (6.860.18 SD) and the permuted p-
value for the pH difference was 0.01 for 5,000 random group
assignments for membership in the super haplogroup cluster (U,
K, UK).
The present study design intentionally avoided some peri-
mortem artifacts by pre-selecting subjects with rapid deaths and
without recorded agonal factors in the autopsy database. The pH
association did not appear spurious due to differences in
assignment of cases and controls as the distribution was equally
distributed for psychiatric cases and controls between U, K, UK
super haplogroup and the remaining haplogroups. The pH shift
towards the right for the U, K, UK super haplogroup and all other
subjects (Fig. 4) showed that the lowest nine brain pH readings
were all from subjects in the other super haplogroups besides U,
K, or UK. Removing the lowest five pH subjects did not change
the association of pH nor reduce the bootstrap significance of the
difference between haplogroups. However, to exclude if the effect
could be primarily related to factors like postmortem interval or
agonal factors, we controlled for both effects. The PMI was not
different between the U, K, UK super haplogroup and the
remaining haplogroups, and including PMI in ANCOVA did not
reduce the significance of the pH differences (p=0.0007 with PMI
as a covariate).
Discussion
The present study analyzed mtDNA sequence data collected
from 17 major yet diverse haplogroups residing in Southern
California. Over 1.6610
6 bp of high quality mtDNA genetic data
was generated. Mitochondrial array resequencing data was
99.999% identical to conventional CE sequencing [69] indicating
that the mitochondrial resequencing array is a reliable method.
The mitochondrial microarray, however, showed a large N call
rate, which may be improved by using similar PCR conditions as
the National Institute of Standards and Technology. Additionally,
changing the base pair calling algorithm [69] could increase the
average call rate to .99% across the entire mtDNA genome
[69,70,86]. In addition, the mitochondrial microarray showed a
high heteroplasmy level using the calculation method of Coon et al.
[65] for the ND4L T10652C SNP which could not be validated
entirely with SNaPshot or allele specific PCR.
The main finding relevant to schizophrenia was an increased
number of synonymous base substitutions in mtDNA in DLPFC.
The first method used a codon purifying selection method [84] in
coding regions only, and examined pair wise concordances of
sequences to establish, for each group, whether there were
synonymous substitutions in codons. The rate of synonymous
substitutions in schizophrenia was 22% higher compared to the
control rate (p=0.0017).
The second calculation method was a transversion/transition
rate bias (R) [84] performed for each group separately. R was
Figure 3. Scatter plot of the heteroplasmy levels of ND4L
T10652C calculated from the Affymetrix mitochondrial rese-
quencing chip by method of Coon et al. [65] on the y-axis and
allelic specific PCR (x-axis truncated).
doi:10.1371/journal.pone.0004913.g003
Table 4. Codon-based test of purifying selection for pair wise analysis between sequences.
Group [A] dS.dN [B] dN=dS [A]/[A+B] [A]/[A+B]/Control Chi-Square p-value
BD 193 239 0.44 (1.11) 2.42 0.119
MDD 202 296 0.40 (1.01) 0.03 0.85
SZ 247 257 0.49 (1.22) 9.82 0.0017
Control 297 445 0.40 (1.00) NA NA
Values of p,0.05 were considered significant and tabulated; column [A] shows the number of significant pair wise comparisons. Subjects with SZ showed a 22%
increase in the number of synonymous substitutions relative to non synonymous mtDNA substitutions in DLPFC (p=0.0017).
Column [A] is the number of SNPs by group for purifying selection; column [B] is the number of SNPs by group for neutral selection. The column showing the ratio of
[A]/[A+B] is to normalize the purifying SNPs by the total SNPs for the group. The chi-square values are calculated for columns [A] and [B] and for SZ group compared to
the control group, there was a higher rate of synonymous substitutions.
doi:10.1371/journal.pone.0004913.t004
Table 5. Transition/transversion bias calculation for mtDNA
coding sequences shows difference between SZ and control
group substitution.
Group Transition/Transversion Bias (R) (R)/Control)
SZ 36.61 2.25
BD 13.28 0.81
MDD 21.02 1.29
C 16.27 1.00
*R=[A*G*k1+T*C*k2]/[(A+G)*(T+C)]. Codon positions included were
1st+2nd+3rd. All calculations were conducted in MEGA4 [84].
This result is consistent with the increased synonymous substitution rate in SZ
shown in Table 4.
doi:10.1371/journal.pone.0004913.t005
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ratio (transition/transversion) data was examined on individual
mitochondrial complex functional grouping levels, the rate for R
in mitochondrial complex I was 10 fold higher in SZ compared to
controls. This suggests an increase in the number of substitutions
in DLPFC in SZ compared to controls preferentially in mtDNA
transcripts in complex I. There is a previous report of age related
increases of synonymous substitutions in brain [87]. It has been
previously demonstrated that there is an increase in the rate of
substitutions in somatic mtDNA in brain[21]. Increased synony-
mous substitutions have also been reported in blood mtDNA in SZ
[58]. A possible mechanism could be a result of nuclear gene
defects in genes such as POLG. POLG is a proof reading enzyme
for mtDNA which was shown in association to Parkinson’s disease
[88,89]. POLG knock down mice have increased mtDNA
synonymous substitution rates [90].
Heteroplasmy results by microarray at ND4L 10652 were
largely not concordant with two separate validation attempts. One
MDD subject was shown to have 81% heteroplasmy with
microarray, 88% heteroplasmy with allele specific PCR, the C
allele with direct sequencing and was not run with SNaPshot. Only
two additional subjects were confirmed to have ‘significant’
heteroplasmy levels for this rare variant, 0.47% compared to the
microarray resequencing results which were 69% and 58%. These
three subjects had psychiatric disorders and were within the M, N
and pre HV haplogroups. Further work is required to determine
why the microarray T10652C mtDNA variants could not be
validated, since the putative carriers had a four-fold higher relative
risk of psychiatric disorders compared to controls, and died at
younger ages both in control and psychiatric comparisons.
In a study of 18 Alzheimer cases and 19 controls there was a
statistically significant difference reported for the T10652 expected
reference signal (p,0.05), although it was not specified if it was the
C allele substitution [65]. Given the fact that this SNP was not
present in 2,704 sequences distributed among major haplogroups
and only reported in one L2b individual (Mitokor 568 sequence),
Table 6. pH in postmortem brain showed significant association with three mtDNA SNPs.
Position mtDNA (RCRS) Base A* G* A# G# Location Amino Change
p-value of pH
association empirical
12308 A 2357 347 56 15 tRNA Leu 0.000435
11467 A 2357 347 55 15 ND4 Leu -.Leu 0.000589
12372 G 390 2314 15 58 ND5 Leu -.Leu 0.001118
The empirical p-values were from PLINK with permutation. The three mtDNA SNPs define the super- haplogroup U, K, UK matrilineages. This super-haplogroup
demonstrated significantly increased postmortem pH (mean 7.060.18 SD) compared to the other haplogroups combined (mean 6.860.18 SD); permuted p-value was
0.01 for 5,000 random group tests. This robust association was not altered by differences in PMI, agonal factors, or case-control assignment differences between
haplogroups. The PMI was not different between the U, K, UK super haplogroup and the remaining haplogroups, and including PMI in ANCOVA did not reduce the
significance of the pH differences (p=0.0007 with PMI as a covariate).
*The A and G columns refer to Ingman database frequencies (URL http://www.genpat.uu.se/mtDB/), while the A# and G# columns refer to observed frequencies in this
study.
doi:10.1371/journal.pone.0004913.t006
Figure 4. The super haplogroup (U, K, UK) showed a shift in postmortem brain pH, and this finding was significant following
permutation analysis. The histogram shows the frequency of the pH (bars) for the super haplogroup (red) compared to all other matrilineages
(blue). The accumulated percentage (right y-axis) is shown as two lines with the super haplogroup (red line) and all other matrilineages (blue line).
There were no subjects with a prolonged death, or agonal factors as rated according to the Hardy et al. scale [98]. PMI differences did not account for
this significant effect, as PMI was equivalent between the super haplogroup and other haplogroups.
doi:10.1371/journal.pone.0004913.g004
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study is suspect since both studies used Affymetrix mitochondrial
resequencing arrays.
With the above caveat in mind, we nevertheless found a
common haplotype of four SNPs – T10652C, T14783C,
G15043A, and T9540C in 15 of 16 subjects in the M, N and
pre HV haplogroups. Individuals with this haplotype cluster
separately from the remainder of subjects near the L1 and L2
haplogroups suggesting an ancient origin. It is tempting to
speculate that the common haplotype might be a marker for the
increased substitutions in brain mtDNA which is associated with
younger ages of morbidity in both psychiatric disorder and control
groups. The haplotype (T14783C, G15043A, and T9540C) could
be further investigated for functional mitochondrial differences. A
trend for an association for each SNP was found (T14783C,
G15043A, T9540C) suggesting that although these SNPs did not
pass permutation corrected p values,0.05, there is a putative
haplotype association with risk for psychiatric disorders that can be
tested in larger sample sizes.
There was a recent finding that schizophrenia was over-
represented in the HV haplogroup with increased relative risk
(odds ratio) of 1.8 [64]. Our findings for haplogroup association
with psychiatric disorders were significant for pre HV showing
increased risk, T showing a protective factor. While based upon a
small sample size these findings clearly warrant replication in a
larger sample size.
Brain pH showed an association with super haplogroup (U, K,
UK) which had a significantly higher pH, i.e. a 1.54 fold decrease in
H+ concentration compared to the remaining haplogroups. If
haplogroup specific variations in mtDNA can produce alterations of
pH levels in human brain, then it could be anticipated that disease
associations might also be seen in a larger study. In fact, there was a
protective effect of the haplogroup UJKT [91] in Parkinson’s
disease, which taken together with evidence of higher brain pH in
the U, UK, and K subjects might be an indicator of more adaptive
brain physiological responses to hypoxia. It has been hypothesized
that certain haplogroups are more tightly coupled in the following
order from most to least (H.J=T.U.UK) [92]. The hap-
logroups that are more tightly coupled will generate more reactive
oxygen and the less coupled U and UK would have looser coupling
efficiency and generate the least ROS in this group. This loose
coupling could explain the higher pH, due to less excess
mitochondrial oxidation and decreased H+ ion gradients in the
outer membrane. A mitochondrial component in diathesis to
schizophrenia and mood disorders might involve more tightly
coupled OXPHOS processes that occur in H haplogroups on the
left of the inequality expression. This tendency towards association
of psychiatric disorders with H haplogroups was observed in this
study and other studies [58,64].
Synonymous base pair changes were observed in mtDNA genes
in DLPFC: ND2, ND4L, ND6, and Cytb. Three of these
‘associated’ genes ND2, ND4L, and ND6, are located in complex
I of the mitochondrion. Associations with complex I mtDNA SNPs
such as ND4 T12027C and ND5 C12403T have been reported in
schizophrenia [59,60] and ND1 T3644C mutation in complex I in
BD [52]. A decreased expression of complex I mitochondrial
transcripts in SZ was recently shown in DLFPC [93]. In addition,
a decreased expression of nuclear encoded subunits of complex I
was shown in SZ in prefrontal cortex and striatum [94]. This is
consistent with inhibition of complex I by various antipsychotics.
Haloperidol potently inhibits complex I, followed by chlorprom-
azine, fluphenazine and risperidone while the atypical neuroleptic,
clozapine, did not inhibit complex I activity in mouse brain slices
[95]. Neuroleptics such as haloperidol and flupenthixol reduce
complex I activity in brain of subjects with SZ [96]. The
production of superoxide anion O22, the principle agent of
oxidative stress, is reduced in brain homogenates from rats treated
with flupenthixol and reduced in brain tissue and lymphocytes
from schizophrenics receiving neuroleptic medication [96]. These
studies support the view that a classical neuroleptic such as
haloperidol inhibits mitochondrial complex I and reactive oxygen
species (ROS) [97]. Complex I deactivation pathophysiology is
observed in postmortem brain at both the protein and mRNA
levels and the question of whether medications and interactions
with mtSNPs requires additional studies. It might be that mtSNPs
modulate the responses to antipsychotic treatment at the
mitochondrial level as suggested by a recent mtDNA SNP
pharmacogenomic study [61].
In summary, this study analyzed mitochondrial DNA variation in
brain and found increased mitochondrial DNA substitutions in
subjects with SZ compared to controls similar to findings in blood
[58] forSZ.Haplogroupassociationswithriskandprotectivefactors
for SZ and BP were found that require further replication. One
MDD subject carried essentially a homoplasmic mutation in
DLPFC at ND4L T10652C, and two subjects with SZ showed
less than 1% heteroplasmy; however, the pathological significance
of the low levels of this non synonymous heteroplasmic mutation is
unknown. This study replicated that low levels of heteroplasmic
non-synonymous mutations are found in the brain [87]. A third
findingshowedthat the UK macro haplogroup maintained a higher
pH in response to terminal brain hypoxia. The present findings
taken together could be useful in mitochondrial medicine for earlier
diagnosis and treatment of brain related disorders based upon
recognition of haplogroup and individual susceptibility factors.
Methods
Ethics Statement
Informed consent to allow genetic testing was obtained from the
next of kin for each sample and the collected samples were
approved by the University of California, Irvine Institutional
Review Board.
Synonymous and non synonymous substitutions in mtDNA in
all coding and control regions were identified in dorsolateral
prefrontal cortex (DLPFC) by microarray resequencing of
schizophrenia (SZ), bipolar disorder (BD), major depressive
disorder (MDD), and control (C) subjects. The demographics for
the study are shown for the mitochondrial DNA resequencing
analysis (Table 7). A total of 77 subjects (12 with BD, 14 with SZ,
15 with MDD, and 36 controls) were initially studied. The
majority of subjects were identified as Caucasian (71), the
remaining were African - American (1), Asian (2), Other (2), and
Pacific Islander (1). Age, gender, pH, PMI and DNA crossing
threshold (Ct) of each subject are summarized in Table 7. The
average pH for MDD subjects was slightly higher than all other
groups and the mean age for SZ was lower than all other groups.
We included subjects with a rapid death, and no known agonal
factors related to chronic illness. Rapidity of death was scored
according to the Hardy et al. scale [98]. A rapid death occurs
within 1 hr from agonal onset based upon coroner’s office
estimates and is rated on the Hardy scale as 1 or 2. For qualitative
purposes, examples of agonal factors are medical conditions at the
time of death such as coma, pyrexia, skull fracture, hypoxia,
dehydration, multi-organ failure, seizures and ingestion of
neurotoxic substances [98,99,100,101]. Each case and control
was screened by an extensive review of the medical examiner’s
conclusions, coroner’s investigation, medical records, toxicology
results, and interviews of the decedent’s next-of-kin.
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samples from SZ, BD, MDD, and controls were collected
previously from the Orange County Medical Examiner’s Office
[102]. Each brain underwent a gross neuropathological examina-
tion to rule out lesions, infarcts, and gross abnormalities [103].
The neuropathology written opinion was based upon careful
examination of high resolution digital images of 28 coronal slices
per whole brain. The 1 cm coronal slabs were frozen at 2140uC,
placed into sealed bags, and transferred to 280uC storage. A best
estimate clinical diagnosis was based upon DSM-IV criteria
applied to medical and hospital records, and next of kin interviews
conducted by two psychologists, and were reviewed by a senior
psychiatrist.
The dorsolateral prefrontal cortex (DLPFC Brodmann areas 9/
46) was dissected from coronal slabs on the left side using
neuroanatomical landmarks rostral to the corpus callosum from
the medial frontal gyrus on a platform cooled with dry ice. The
dissected prefrontal regions from each brain were weighed frozen
(,100 mg) and processed. DNA was extracted from brain tissue
using a standard Trizol protocol. Briefly, the DNA was extracted
from the phenol phase and precipitated with ethanol. The DNA
was then washed twice with 0.1 M sodium citrate in 10% ethanol
and solubilized in 8 mM NaOH. The extraction technique
provided excellent recovery and quality of nucleic acid assessed
by qPCR (Table 7).
Affymetrix Mitochondrial Resequencing Arrays
Genomic DNA obtained from DLPFC was used on Affymetrix
GeneChip Mitochondrial Resequencing Arrays 2.0 following
manufacturer’s protocol (Affymetrix, Santa Clara, CA). Briefly,
the mitochondrial resequencing chip has both strands of the entire
human mitochondrial coding sequence (15,451 bp) arrayed; both
strands of an additional 12,935 bp (84% of coding DNA) are
arrayed in duplicate. We used 300 ng of genomic DNA to amplify
the mitochondrial genome in three overlapping long PCR
fragments and pooled equimolar amounts of amplicon using the
protocol from the Affymetrix GeneChip Resequencing Reagent
Kit. The reliability of mtDNA resequencing was determined by
comparing mtDNA sequence on the same subjects measured twice
by the resequencing microarray. The accuracy of the resequencing
microarray results was compared to conventional ABI direct
sequencing for three subjects.
Statistical Analysis
Frequencies of assigned allele calls were compared by using the
allele chi-square test in PLINK for a case - control analysis of MT
chromosome, and running permutation analysis (n=50,000
permutations) for determining empirical p-values (URL: http://
pngu.mgh.harvard.edu/purcell/plink/) [79]. Associations between
mtDNA ethnic specific haplogroup variants and postmortem pH
values were tested in PLINK.
Tests of substitution rate differences between groups were
conducted as follows. The pair wise comparisons of substitutions
between SZ, BD, MDD, and controls were calculated with
Molecular Evolutionary Genetics Analysis (MEGA software
version 4.0) [84] using the Nei-Gojobori method [84,85,103].
The probability of rejecting the null hypothesis of strict-neutrality
of selection (dN=dS) in favor of the alternative hypothesis
(dN,dS) was calculated for the test statistic (dS2dN). The
variance of the difference was computed using the bootstrap
method (10,000 replicates). Values of p,0.05 were considered
significant and tabulated for each group and group frequencies
were tested with Pearson’s chi-square. An estimation of the
transition/transversion bias for each group was also calculated in
MEGA4 [84].
Haplogroup assignment and mtDNA transversions/transitions
were determined with the MitoMaster database [104,105] in the
Center for Molecular and Mitochondrial Medicine and Genetics.
This uses neighbor joining distances to assign haplogroups based
upon specific mtDNA haplotype.
Heteroplasmy was screened by microarray calculation with the
method of Coon et al. [65]. The microarray signal intensity data
from all four alleles (A, C, G, and T), on both the sense and
antisense strands formed the relative expected allele intensity. The
expected allele was called using the revised Cambridge Reference
Sequence (rCRS) [106] (Accession # REFSEQ AC_000021.2
gi:115315570).
Direct Sequencing and Cloning of ND4L T10652C Variant
To validate the ND4L T10652 variant, PCR was performed on
the 17 DLPFC samples that showed the highest levels of
heteroplasmy at this locus with the resequencing arrays. These
subjects were in the N (N1B1, pre HV) and M (D1) haplogroups.
PrimersweredesignedusingPrimer3software(Totowa,NJ)(forward
59-TCGCTCACACCTCATATCCTC-39 and reverse 59-
GGCCATATGTGTTGGAGATTG-39). PCR reactions were run
on a 2% agarose gel and fragments were cut out and purified using
the QIAquick Gel Extraction Kit (Qiagen, Valencia, CA).
Sequencing reactions were run using the forward PCR primer and
the Big Dye Terminator Kit (Applied Biosystems, Foster City, CA).
Products were purified using a DyeEx 2.0 Spin Kit (Qiagen) and
analyzed onanABI Prism3100capillarysequencer.Sequenceswere
read in Geneious (Biomatters, Ltd., New Zealand) for alignment
around mitochondrial locus 10652. The sample showing the highest
heteroplasmy level (81%) by microarray (the MDD sample in
haplogroup D1) was validated by capillary sequencing and used to
create the T allele clone for the standard curve for SNaPshot
analysis. A second sample, showing very low heteroplasmy by
microarray, was chosen for the C allele clone for the standard curve.
Both clones were used for PCR with the ND4L primers and PCR
products were gel purified and cloned into the pCRH2.1-TOPOH
vector using the TOPO-TA CloningH Kit (Invitrogen Life
Technologies, Carlsbad, CA). Transformations used One ShotH
Mach1
TM-T1
R competent cells and were plated out on LB plates
with X-gal and kanamycin. White and light blue colonies were
selected and minipreps were purified using the PureLink
TM Quick
Plasmid Miniprep Kit (Invitrogen) according to the manufacturer’s
instructions. Clones were tested for correct insert sequence and
orientation using the M13 forward and reverse primers.
Table 7. Demographics of subjects from which DLPFC
mtDNA was resequenced.
Group N pH Age (yrs) Sex PMI (hr) DNA (Ct)
Mean SD Mean SD M/F Mean SD Mean SD
BD 12 6.87 0.16 50 17 9/3 25.1 9.6 29.0 1.1
MDD 15 6.96* 0.19 51 15 11/4 24.6 6.7 30.3 2.2
SZ 14 6.87 0.24 45* 9 11/3 24.0 12.1 30.6 2.5
C 36 6.81 0.19 53 13 31/5 23.0 8.0 30.0 2.2
All subjects had a rapid death and absence of prolonged hypoxia prior to death.
An increased pH was found in MDD compared to the C group. Subjects with SZ
died at younger age than C subjects. The Ct for extracted DNA was measured
by qPCR for genomic DNA and was similar between groups.
doi:10.1371/journal.pone.0004913.t007
Mitochondrial Variants
PLoS ONE | www.plosone.org 9 March 2009 | Volume 4 | Issue 3 | e4913SNaPshot Standard Curve
Established clones for the T and C alleles at ND4L 10652 were
used to create the standard curve for SNaPshot analysis. The ABI
Prism SNaPshot Multiplex Kit (ABI, Foster City, CA) was used
according to the manufacturer’s protocol with 0.10 pmols of
template. Seven dilutions were made for the standard curve: 100%
C allele, 83% C allele, 10% Callele, 5% C allele, 1%C allele,.1%C
allele and 100% T allele. The SNaPshot single-base extension
reactions were run on the 3100 Genetic Analyzer (ABI, Foster City,
CA). DNA fragment data was analyzed using the Peak Scanner
Software v1.0 (ABI, Foster City, CA) to obtain the ratio of the peak
heights corresponding to each allele for the different levels of
heteroplasmy in the standard curve. Once a calibration curve was
established with varying dilutions of each clone, 24 mtDNA samples
from DLPFC that showed varying levels of heteroplasmy with
microarray were run using the SNaPshot Multiplex Kit.
Allele Specific PCR
An allelic specific real-time detection and quantification of
mtDNA variants was implemented to more precisely confirm the
percentage heteroplasmy observed in the microarray experiment.
Low levels of heteroplasmy down to 0.02% were detected using a
method derived from Strand et al. [107]. This involved an allele
specific amplification by PCR [108], followed by the quantification
of the amounts of T and C alleles using the Light Cycler 480 (Roche,
Indianapolis, IN). The standard curve was constructed from the
10652 clones (see above) using absolute copy number proportions of
each allele (500 to 1 million copies). Copy numbers of each allele for
the 77 DLPFC samples were then calculated from the standard
curve after an allelic specific PCR to determine the unknown ‘‘Cp’’
of each allele. The heteroplasmy was calculated as the % C over the
total (C+T). High specificity and sensitivity for the mutant C allele
wereachieved byblocking non-specific amplification of the wild type
allele with an amine blocked T specific primer.
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